Scilex Holding Co. — Form 8-K Summary
Business context and reporting period
Scilex Holding Company filed a Form 8-K reporting events dated July 5, 2023. Its controlling stockholder, Sorrento Therapeutics, Inc., and Sorrento subsidiary Scintilla Pharmaceuticals, Inc. are debtors in Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas.
Financing and key financial terms
- The Bankruptcy Court entered an interim order approving a junior debtor-in-possession financing facility to be provided by Scilex to the debtors.
- The Junior DIP Facility has a base amount of up to $20.0 million, plus a 1% commitment fee, a 1% funding fee, and the DIP Lender Holdback specified in the interim order.
- The facility is non-amortizing, super-priority, and junior secured. It is subordinated to the existing Senior DIP Facility provided by JMB Capital Partners Lending, LLC.
- The Junior DIP Facility bears interest at 12.00% per annum, payable in kind monthly and at maturity. The rate increases by 2.00% per annum during an event of default.
- Upon repayment, the debtors must pay a cash exit fee equal to 2% of the aggregate principal amount of the Junior DIP Facility on the draw date.
- The filing does not provide Scilex’s revenue, profit, cash flow, margins, balance-sheet liquidity, or debt balances apart from the disclosed DIP facilities.
Material changes versus the prior comparable period
The filing is transaction-focused and does not present comparative financial statements or period-over-period operating results. The material development is Scilex’s agreement to provide interim postpetition financing to its controlling stockholder and affiliate debtors amid a near-term liquidity shortfall.
Outlook, risks, contingencies, and unusual items
- The Senior DIP Facility has commitments of up to $75.0 million and matures July 31, 2023. The debtors stated that their liquidity was expected to last only until July 7, 2023.
- The Junior DIP Facility is expected to mature on the earliest of specified events, including September 30, 2023, the effective date of a Chapter 11 plan, a qualifying asset sale, acceleration, dismissal or conversion of the bankruptcy cases, or July 31, 2023 if a final order has not been entered by then.
- The Junior DIP Facility cannot mature before the Senior DIP obligations’ maturity date as in effect on the interim-order date.
- The debtors were authorized to make a single draw after satisfaction of applicable conditions precedent. The filing does not clearly state whether the draw occurred or the amount ultimately funded.
- Final approval was expected to be sought at a July 24, 2023 hearing. Definitive loan and security documentation was to be completed by the earlier of 15 business days after the interim order or entry of the final order.
- Scilex received a right of first refusal to provide future debtor-in-possession financing during the Chapter 11 cases.
- Key risks include failure to obtain final court approval, inability to satisfy financing conditions, repayment and subordination risk, continued liquidity pressure at the debtors, bankruptcy-case outcomes, and risks identified in Scilex’s SEC filings.
Important facts for investors to verify
- Whether the Junior DIP Facility was actually drawn, and the final amount funded including fees and any holdback.
- Whether the Bankruptcy Court entered the final order and whether definitive financing documents were executed.
- The status, maturity, outstanding balance, and repayment priority of the Senior DIP Facility.
- Scilex’s exposure to repayment losses, accrued payment-in-kind interest, fees, and the 2% exit fee.
- Subsequent developments in Sorrento’s Chapter 11 cases, including any plan, asset sale, dismissal, conversion, or financing replacement.
- Scilex’s available liquidity and operating results, which are not provided in this 8-K.